Open ReMIE: A national platform for therapeutic research on emerging infectious diseases
Launched in 2025, Open-ReMIE is a national platform dedicated to therapeutic clinical research on emerging infectious diseases in France led by ANRS MIE and co-led by Hospices Civils de Lyon.
Last updated on 01 April 2026
What is Open ReMIE?
OPEN-ReMIE , or the National Operational Research Network for Emerging Infectious Diseases, is a national platform dedicated to interventional and observational clinical studies on emerging infectious diseases (EID) in France.
Structured around a network of healthcare facilities, research laboratories, and institutional partners, OPEN-ReMIE aims to accelerate the implementation of clinical trials in response to epidemics and pandemics.
Open-ReMIE: A rapid and effective response to health crises
Inspired by the concept of the “Plan Blanc” crisis mechanism for deployment by French hospitals, Open ReMIE acts as a “Plan Blanc for clinical therapeutic research”, enabling the rapid mobilisation of resources and infrastructures in the event of a health crisis. OPEN-ReMIE is one of the measures of the Emerging Infectious Diseases and Chemical, Biological, Radiological and Nuclear Threats acceleration strategy aimed at strengthening our preparedness in the face of the risks of a new major health crisis (in the coming years and our response capacity at national level, in conjunction with the European level).
Open-ReMIE missions:
- Structure a national clinical research network for an effective response to epidemics.
- Accelerate clinical trial implementation through innovative methodologies and optimised processes.
- Promote collaboration between academic and industrial players, as well as with international research networks.
- Develop training and communication tools to strengthen capacity to respond to health crises.
A network of committed players
Open-ReMIE is coordinated by Inserm/ANRS Emerging Infectious Diseases and co-coordinated by the Hospices Civils de Lyon (HCL). Its scientific leaders are Prof. Florence Ader (HCL) and Prof. Karine Lacombe (APHP). It brings together a group of hospital institutions, research laboratories and experts in methodology, epidemiology and biostatistics.
Open-ReMIE: An integrated system in Europe and beyond
The platform is part of a collaborative effort at multiple levels, aimed at improving the coordination of clinical trials and the various stakeholders involved in clinical research on emerging infectious diseases.
It works closely with other key initiatives for organizing clinical research on emerging infectious diseases, including I-REIVAC Emergence (France 2030) and Renarci (F-CRIN) at the national level, PROACT EU-Response (Horizon Europe) at the European level, and STRIVE at the international level.
It actively participates in efforts to coordinate and facilitate the implementation of clinical research during crises, particularly in Europe through the Pandemic Preparedness Partnership (BE READY).
Operation and governance
The main objective of the platform is to adopt a flexible and scalable mode of operation, capable of adapting to the specific needs of health crises. Over time, OPEN-ReMIE will develop processes and infrastructures to enable rapid and coordinated resource mobilisation in the event of an epidemic or pandemic to evaluate different treatments.
An organization structured into six working groups
To ensure its effectiveness, OPEN-ReMIE is based on six operational components (Work Packages – WP) that will address all clinical research needs and cover all activities necessary for the implementation of hospital-based clinical trials, particularly in the context of health crises :
- WP1 : Regulatory Procedures and Promotion
Establishment of an operational and regulatory framework adapted to crisis situations to ensure patient safety, facilitate the conduct of clinical studies, and promote innovative approaches such as decentralization and digitization.
- WP2 : Network of clinical sites
Establishment of a national network of clinical centers specializing in infectious diseases, organized into two complementary tiers, to ensure rapid mobilization adapted to the dynamics of epidemics. Deployment of a regional network enabling patient enrollment across the entire country, with flexible protocols ensuring patient safety. Positioning OPEN-ReMIE as a one-stop shop for therapeutic research during inter-crisis periods, in collaboration with academic, institutional, and industrial partners at the national and international levels.
- WP3 : Methodology and Management Centers
Structuring of the methodological, statistical, and data management components to ensure the evaluation of treatment efficacy and safety, with the development of generic protocols and innovative approaches such as in silico trials. Organization of data interoperability, management, and utilization throughout the studies. Establishment of harmonized and adaptable monitoring to ensure the quality of studies in accordance with the health context.
- WP4 : Laboratory Network and Biobank
Establishment of a national network of multidisciplinary biological analysis laboratories covering microbiology/virology, immunology, and pharmacology to ensure pathogen characterization, immune response analysis, and treatment monitoring. Organization of the management, storage, and utilization of biological samples through the ANRS MIE centralized biobank. Contribution to the development of protocols to define the necessary samples in line with the study objectives.
- WP5 : Drug Supply Chain, Pharmacovigilance, and Safety
Organization of the therapeutic component of platform trials, structured around the drug supply chain and pharmacovigilance to ensure treatment availability and patient safety. Implementation of procedures covering the drug lifecycle (procurement, logistics, management, and disposal) as well as the monitoring of adverse events and risk management. Definition, in collaboration with clinical sites, of protocol termination rules, with mechanisms adapted to crisis and inter-crisis contexts.
- WP6 : Training, Communication, Promotion, and Dissemination
Definition and implementation of a communication strategy aimed at promoting OPEN-ReMIE’s activities to the scientific community and the general public. Promotion of the platform’s clinical trials, events, and results.
Active contribution to combating misinformation by disseminating reliable information and highlighting resources and training on emerging infectious diseases.
A platform integrated into the national strategy for preparedness and response to health crises
OPEN-ReMIE will work in close collaboration with the Acceleration Strategy for Emerging Infectious Diseases – France 2030, which aims to prepare France to address risks that could trigger a new major health crisis and to limit its impacts or even prevent it. More specifically, the platform will coordinate with initiatives supported under the innovation component dedicated to the development of innovative countermeasures, by monitoring maturation projects that can benefit from clinical infrastructure to advance along the research continuum, and through close coordination with other funded national platforms: An inter-platform committee was established in September 2025 to bring together these various national initiatives and ensure their coordination and resource sharing in the event of a crisis.
An inter-platform committee was established in september 2025 to bring together these various national initiatives and ensure their coordination and resource sharing in the event of a crisis.
Project Timeline
The project began on March 1, 2025, and will run for five years, with funding provided by the Agence Nationale de la Recherche (the French National Research Agency; ANR-24-MIEM-0003) as part of the strategy to accelerate research on emerging infectious diseases under the France 2030 Plan.
The kick-off meeting took place on March 21, 2025, to formalize the activities to be implemented and align all partners on the objectives and upcoming milestones. Read the press release.
The consortium meets twice a year at its General Assemblies.
Contact : open-remie@inserm.fr